Blood Cancers

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

By

Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).

Markers Found on Solid Tumors Are a Target for CAR T Cell Therapy

Markers Found on Solid Tumors Are a Target for CAR T Cell Therapy

By

Chimeric antigen receptor (CAR) T cell therapy is now moving toward effectiveness against solid tumors, based on recent work in mouse models. CAR T cell therapy has already had successes against aggressive blood cancers.

Frailty Is a Concerning Factor Among Young Bone Marrow Transplant Survivors

Frailty Is a Concerning Factor Among Young Bone Marrow Transplant Survivors

By

Incidence of frailty among young survivors of bone marrow transplant is similar to that of the elderly population, and increases the risk of death compared with nonfrail survivors.

Bone Pain Due to White Blood Cell Growth Factors

Bone Pain Due to White Blood Cell Growth Factors

By

How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?

Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood Cancers

By

In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

By

Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.

Inherited Gene Variation Linked to an Increased Risk of Pediatric Acute Lymphoblastic Leukemia (ALL)

Inherited Gene Variation Linked to an Increased Risk of Pediatric Acute Lymphoblastic Leukemia (ALL)

By

Researchers studying two generations of a family affected by pediatric ALL identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.

High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With Amyloidosis

By

Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.

Proactive telephone support reduces unplanned hospitalizations in blood cancers

Proactive telephone support reduces unplanned hospitalizations in blood cancers

By

Implementing proactive telephone support reduced unplanned hospitalizations among patients with blood cancers by 70%.

New drug shows sustained benefit at 2 years in rare blood cancer

New drug shows sustained benefit at 2 years in rare blood cancer

Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia.

Genetically engineered immunotoxin shows early promise for B-cell malignancies

By

DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be effective in a small group of patients with relapsed/refractory B-cell malignancies, according to clinical trial results.

High-cost blood cancer drugs deliver high value

By

A recent analysis suggests that breakthrough therapies for blood cancers may, in a majority of cases, provide reasonable value for money spent.

New test helps guide treatment for bone marrow transplant patients with GVHD

By

A new test can assist in the treatment of patients with graft-versus-host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants.

Immunotherapy shows clinical benefit in relapsed transplant recipients

Immunotherapy shows clinical benefit in relapsed transplant recipients

By

Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.

Short chemotherapy regimen can control immune disease after some bone marrow transplants

By

A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of blood cancer

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

New test predicts survival in patients with leukemia

New test predicts survival in patients with leukemia

Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukemia.

First-in-class metabolism drug shown to be clinically active against advanced blood cancers

By

AG-221, a novel inhibitor of isocitrate dehydrogenase 2-mutant metabolic enzyme, showed early promise in patients with advanced and refractory blood cancers harboring IDH2 mutations.

Epigenetic therapy clinically active against several blood cancers

Epigenetic therapy clinically active against several blood cancers

By

Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.

Allergies increase risk of blood cancers in women

By

A team of scientists looking into the interplay of the immune system and cancer have found a link between a having a history of airborne allergies with risk of blood cancers in women.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs